Overcoming endocrine resistance in breast cancer

Current Cancer Drug Targets

Volumn 10, Issue 5, 2010, Pages 519-528

  Madaio, R A ^a   Spalletta, G ^b   Cravello, L ^b   Ceci, M ^c   Repetto, L ^c   Naso, G ^d  

^a Piazza San Bartolomeo All'Isola 21   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c INRCA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Breast cancer; Estrogen receptor; Hormone resistance

Indexed keywords

ANASTROZOLE; BRCA1 PROTEIN; CYTOCHROME P450; CYTOCHROME P450 2D6; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EVEROLIMUS; FULVESTRANT; GEFITINIB; LAPATINIB; LETROZOLE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; RALOXIFENE; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; ANTINEOPLASTIC AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RELAPSE; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG RESISTANCE; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; MOLECULAR INTERACTION; ONTOGENY; POSTMENOPAUSE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; BREAST TUMOR; FEMALE; METABOLISM; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; RECEPTORS, ESTROGEN;

EID: 77956514087     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910791517226     Document Type: Article

References (89)

1. Tsai, M. J.; O'Malley, B. W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 1994, 63, 451-486.
2. Batistuzzo de Medeiros, S. R.; Krey, G.; Hihi, A. K.; Wahli, W. Functional interactions between the estrogen receptor and the transcription activator Sp1 regulate the estrogen-dependent transcriptional activity of the vitellogenin A1 io promoter. J. Biol. Chem. 1997, 272, 18250-18260.
3. Paech, K.; Webb, P.; Kuiper, G. G.; Nilsson, S.; Gustafsson, J.; Kushner, P. J.; Scanlan, T. S. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997, 277, 1508-1510.
4. Porter, W.; Saville, B.; Hoivik, D.; Safe, S. Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol. Endocrinol. 1997, 11, 1569-1580.
5. Nilsson, S.; Makela, S.; Treuter, E.; Tujague, M.; Thomsen, J.; Andersson, G; Enmark, E.; Pettersson, K.; Warner, M.; Gustafsson, J. A. Mechanisms of estrogen action. Physiol. Rev. 2001, 81, 1535-1565.
6. Tora, L.; White, J.; Brou, C.; Tasset, D.; Webster, N.; Scheer, E.; Chambon, P. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 1989, 59, 477-487.
7. Tzukerman, M. T.; Esty, A.; Santiso-Mere, D.; Danielian, P.; Parker, M. G.; Stein, R. B.; Pike, J. W.; McDonnell, D. P. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol. Endocrinol. 1994, 8, 21-30.
8. Benecke, A.; Chambon, P.; Gronemeyer, H. Synergy between estrogen receptor activation functions AF1 and AF2 mediated by transcription intermediary factor TIF2. EMBO Rep. 2000, 1, 151-157.
9. Delaunay, F.; Pettersson, K.; Tujague, M.; Gustafsson, J. A. Functional differences between the amino-terminal domains of estrogen receptors alpha and beta. Mol. Pharmacol. 2000, 58, 584-590.
10. Kuiper, G. G.; Enmark, E.; Pelto-Huikko, M.; Nilsson, S.; Gustafsson, J. A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA 1996, 93, 5925-5930.
11. Horwitz, K. B.; Jackson, T. A.; Bain, D. L.; Richer, J. K.; Takimoto, G. S.; Tung, L. Nuclear receptor coactivators and corepressors. Mol. Endocrinol. 1996, 10, 1167-1177.
12. Walter, P.; Green, S.; Greene, G.; Krust, A.; Bornert, J. M.; Jeltsch, J. M.; Staub, A.; Jensen, E.; Scrace, G.; Waterfield, M. Cloning of the human estrogen receptor cDNA. Proc. Natl. Acad. Sci. USA 1985, 82, 7889-7893.
13. Greene, G. L.; Gilna, P.; Waterfield, M.; Baker, A.; Hort, Y.; Shine, J. Sequence and expression of human estrogen receptor complementary DNA. Science 1986, 231, 1150-1154.
14. Korach, K. S.; Emmen, J. M.; Walker, V. R.; Hewitt, S. C.; Yates, M.; Hall, J. M.; Swope, D. L.; Harrell, J. C.; Couse, J. F. Update on animal models developed for analyses of estrogen receptor biological activity. J. Steroid Biochem. Mol. Biol. 2003, 86, 387-391.
15. Weihua, Z.; Saji, S.; Makinen, S.; Cheng, G.; Jensen, E. V.; Warner, M.; Gustafsson, J. A. Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus. Proc. Natl. Acad. Sci. USA 2000, 97, 5936-5941.
16. Ström, A.; Hartman, J.; Foster, J. S.; Kietz, S.; Wimalasena, J.; Gustafsson, J. A. Estrogen receptor beta inhibits 17beta-estradiolstimulated proliferation of the breast cancer cell line T47D. Proc. Natl. Acad. Sci. USA 2004, 101, 1566-1571.
17. Faulds, M. H.; Olsen, H.; Helguero, L. A.; Gustafsson, J. A.; Haldosen, L. A. Estrogen receptor functional activity changes during differentiation of mammary epithelial cells. Mol. Endocrinol. 2004, 18, 412-421.
18. Helguero, L. A.; Faulds, M. H.; Gustafsson, J. A.; Haldosén, L. A. Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 2005, 24, 6605-6616.
19. Shyamala, G.; Singh, R. K.; Ruh, M. F.; Ruh, T. S. Relationships between mammary estrogen receptor and estrogenic sensitivity. II. Binding of cytoplasmic receptor to chromatin. Endocrinology 1986, 119, 819-826.
20. Palmieri, C.; Cheng, G. J.; Saji, S.; Zelada-Hedman, M.; Wärri, A.; Weihua, Z.; Van Noorden, S.; Wahlstrom, T.; Coombes, R. C.; Warner, M.; Gustafsson, J. A. Estrogen receptor beta in breast cancer. Endocr. Relat. Cancer 2002, 9, 1-13.
21. Koehler, K. F.; Helguero, L. A.; Haldosén, L. A.; Warner, M.; Gustafsson, J. A. Reflections on the discovery and significance of estrogen receptor beta. Endocr. Rev. 2005, 26, 465-478.
22. Foulkes, W. D.; Metcalfe, K.; Sun, P.; Hanna, W. M.; Lynch, H. T.; Ghadirian, P.; Tung, N.; Olopade, O. I.; Weber, B. L.; McLennan, J.; Olivotto, I. A.; Bégin, L. R.; Narod, S. A. Estrogen receptor status in BRCA1-and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin. Cancer Res. 2004, 10, 2029-2034.
23. Liu, S.; Ginestier, C.; Charafe-Jauffret, E.; Foco, H.; Kleer, C. G.; Merajver, S. D.; Dontu, G.; Wicha, M. S. BRCA1 regulates human mammary stem/progenitor cell fate. Proc. Natl. Acad. Sci. USA 2008, 105, 1680-1685.
24. Polyak, K.; Weinberg, R. A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9, 265-273.
25. Hosey, A. M.; Gorski, J. J.; Murray, M. M.; Quinn, J. E.; Chung, W. Y.; Stewart, G. E.; James, C. R.; Farragher, S. M.; Mulligan, J. M.; Scott, A. N.; Dervan, P. A.; Johnston, P. G.; Couch, F. J.; Daly, P. A.; Kay, E.; McCann, A.; Mullan, P. B.; Harkin, D. P. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J. Natl. Cancer Inst. 2007, 99, 1683-1694.
26. Razandi, M.; Pedram, A.; Rosen, E. M.; Levin, E. R BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer. Mol. Cell. Biol. 2004, 24, 5900-5913.
27. Baer, R.; Ludwig, T. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Curr. Opin. Genet. Dev. 2002, 12, 86-91.
28. Tong, Q.; Hotamisligil, G. S. Developmental biology: cell fate in the mammary gland. Nature 2007, 445, 724-726.
29. Carroll, J. S.; Liu, X. S.; Brodsky, A. S.; Li, W.; Meyer, C. A.; Szary, A. J.; Eeckhoute, J.; Shao, W.; Hestermann, E. V.; Geistlinger, T. R.; Fox, E. A.; Silver, P. A.; Brown, M. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005, 122, 33-43.
30. Carroll, J. S.; Brown, M. Estrogen receptor target gene: an evolving concept. Mol. Endocrinol. 2006, 20, 1707-1714.
31. O'Lone, R.; Frith, M. C.; Karlsson, E. K.; Hansen, U. Genomic targets of nuclear estrogen receptors. Mol. Endocrinol. 2004, 18, 1859-1875.
32. Osborne, C. K.; Schiff, R. Estrogen-receptor biology:continuing progress and therapeutic implications. J. Clin. Oncol. 2005, 23, 1616-1622.
33. Zilli, M.; Grassadonia, A.; Tinari, N.; Di Giacobbe, A.; Gildetti, S.; Giampietro, J.; Natoli, C.; Iacobelli, S. Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer. Biochim. Biophys. Acta 2009, 1795, 62-81.
34. McKenna, N. J.; Lanz, R. B.; O'Malley, B. W. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 1999, 20, 321-344.
35. Schiff, R.; Massarweh, S.; Shou, J.; Osborne, C. K. Breast cancer endocrine resistance:how growth factor signaling and estrogen receptor coregulators modulate response. Clin. Cancer Res. 2003, 9, 447-454.
36. Weigel, N. L.; Zhang, Y. Ligand-independent activation of steroid hormone receptors. J. Mol. Med. 1998, 76, 469-479.
37. Webb, P.; Nguyen, P.; Shinsako, J.; Anderson, C.; Feng, W.; Nguyen, M. P.; Chen, D.; Huang, S. M.; Subramanian, S.; McKinerney, E.; Katzenellenbogen, B. S.; Stallcup, M. R.; Kushner, P. J. Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol. Endocrinol. 1998, 12, 1605-1618.
38. Kobayashi, Y.; Kitamoto, T.; Masuhiro, Y.; Watanabe, M.; Kase, T.; Metzger, D.; Yanagisawa, J.; Kato, S. p300 mediates functional synergism between AF-1 and AF-2 of estrogen receptor alpha and beta by interacting directly with the N-terminal A/B domains. J. Biol. Chem. 2000, 275, 15645-15651.
39. Kahlert, S.; Nuedling, S.; van Eickels, M.; Vetter, H.; Meyer, R.; Grohe, C. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J. Biol. Chem. 2000, 16, 18447-18453.
40. Barletta, F.; Wong, C. W.; McNally, C.; Komm, B. S.; Katzenellenbogen, B.; Cheskis, B. J. Characterization of the interactions of estrogen receptor and MNAR in the activation of Src. Mol. Endocrinol. 2004, 18, 1096-1108.
41. Font de Mora, J.; Brown, M. AIB1 is a conduit for kinase mediated growth factor signaling to estrogen receptor. Mol. Cell Biol. 2000, 20, 5041-5047.
42. Bedard, P. L.; Freedman, O. C.; Howell, A.; Clemons, M. Overcoming endocrine resistance in breast cancer-are signal transduction inhibitors the answer? Breast Cancer Res. Treat. 2008, 108, 307-317.
43. Dawood, S.; Cristofanilli, M. Endocrine resistance in breast cancer: what really matters? Ann. Oncol. 2007, 18, 1289-1291.
44. Moy, B.; Goss, P. E. Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches. Clin. Cancer Res. 2006, 12, 4790-4793.
45. Musgrove, E. A.; Sutherland, R. L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 2009, 9, 631-643.
46. Miller, W. R. Biological rationale for endocrine therapy in breast cancer. Best Pract. Res. Clin. Endocrinol. Metab. 2004, 18, 1-32.
47. Miller, W. R. Identification and mechanisms of endocrine resistance. Breast Cancer Res. 2008, 10, S19.
48. Johnston, S. R.; Lu, B.; Scott, G. K.; Kushner, P. J.; Smith, I. E.; Dowsett, M.; Benz, C. C. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin. Cancer Res. 1999, 5, 251-256.
49. Schiff, R.; Reddy, P.; Ahotupa, M.; Coronado-Heinsohn, E.; Grim, M.; Hilsenbeck, S. G.; Lawrence, R.; Deneke, S.; Herrera, R.; Chamness, G. C.; Fuqua, S. A.; Brown, P. H.; Osborne, C. K. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J. Natl. Cancer Inst. 2000, 92, 1926-1934.
50. Zhou, Y.; Yau, C.; Gray, J. W.; Chew, K.; Dairkee, S. H.; Moore, D. H.; Eppenberger, U.; Eppenberger-Castori, S.; Benz, C. C. Enhanced NF B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 2007, 7, 59.
51. Lavinsky, R.; Jepsen, K.; Heinzel, T.; Torchia, J.; Mullen, T. M.; Schiff, R.; Del-Rio, A. L.; Ricote, M.; Ngo, S.; Gemsch, J.; Hilsenbeck, S. G.; Osborne, C. K.; Glass, C. K.; Rosenfeld, M. G.; Rose, D. W. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoRand SMRTcomplexes. Proc. Natl. Acad. Sci. USA 1998, 95, 2920-2925.
52. Gutierrez, M. C.; Detre, S.; Johnston, S.; Mohsin, S. K.; Shou, J.; Allred, D. C.; Schiff, R.; Osborne, C. K.; Dowsett, M. Molecular changes in tamoxifenresistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J. Clin. Oncol. 2005, 23, 2469-2476.
53. Herynk, M. H.; Fuqua, S. A. Estrogen receptor mutations in human disease. Endocr. Rev. 2004, 25, 869-898.
54. Fehm, T.; Hoffmann, O.; Aktas, B.; Becker, S.; Solomayer, E. F.; Wallwiener, D.; Kimmig, R.; Kasimir-Bauer, S. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res. 2009, 11, R59.
55. Santen, R. J.; Song, R. X.; Zhang, Z.; Kumar, R.; Jeng, M. H.; Masamura, A.; Lawrence, J. Jr.; Berstein, L.; Yue, W. Long-term estradiol deprivation in breast cancer cells upregulates growth factor signaling and enhances estrogen sensitivity. Endocr. Relat. Cancer 2005, 12, S61-S73.
56. Santen, R. J.; Song, R. X.; Zhang, Z.; Yue, W.; Kumar, R. Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. Clin. Cancer Res. 2004, 10, 337-345.
57. Santen, R. J.; Song, R. X.; Zhang, Z.; Kumar, R.; Jeng, M. H.; Masamura, S.; Yue, W.; Berstein, L. Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention. Endocr. Relat. Cancer 2003, 10, 111-130.
58. Berstein, L. M.; Wang, J. P.; Zheng, H.; Yue, W.; Conaway, M.; Santen, R. J. Long-term exposure to tamoxifen induces hypersensitivity to estradiol. Clin. Cancer Res. 2004, 10, 1530-1534.
59. Johnston, S. R.; Martin, L. A.; Dowsett, M. Life following aromatase inhibitors-were now for endocrine sequencing? Breast Cancer Res. Treat. 2005, 93, S19-S25.
60. Johnson, M. D.; Zuo, H.; Lee, K. H.; Trebley, J. P.; Rae, J. M.; Weatherman, R. V.; Desta, Z.; Flockhart, D. A.; Skaar, T. C. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 2004, 85, 151-159.
61. Goetz, M. P.; Rae, J. M.; Suman, V. J.; Safgren, S. L.; Ames, M. M.; Visscher, D. W.; Reynolds, C.; Couch, F. J.; Lingle, W. L.; Flockhart, D. A.; Desta, Z.; Perez, E. A.; Ingle, J. N. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 2005, 23, 9312-9318.
62. Schroth, W.; Antoniadou, L.; Fritz, P.; Schwab, M.; Muerdter, T.; Zanger, U. M.; Simon, W.; Eichelbaum, M.; Brauch, H. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 2007, 25, 5187-5193.
63. Bonanni, B.; Macis, D.; Maisonneuve, P.; Johansson, H. A.; Gucciardo, G.; Oliviero, P.; Travaglini, R.; Muraca, M. G.; Rotmensz, N.; Veronesi, U.; Decensi, A. U. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian tamoxifen trial. J. Clin. Oncol. 2006, 24, 3708-3709.
64. Ma, C. X.; Adjei, A. A.; Salavaggione, O. E.; Coronel, J.; Pelleymounter, L.; Wang, L.; Eckloff, B. W.; Schaid, D.; Wieben, E. D.; Adjei, A. A.; Weinshilboum, R. M. Human aromatase: gene resequencing and functional genomics. Cancer Res. 2005, 65, 11071-11082.
65. Shou, J.; Massarweh, S.; Osborne, C. K.; Wakeling, A. E.; Ali, S.; Weiss, H.; Schiff, R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl. Cancer Inst. 2004, 96, 926-935.
66. Fan, P.; Wang, J.; Santen, R. J.; Yue, W. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res. 2007, 67, 1352-1360.
67. Knowlden, J. M.; Hutcheson, I. R.; Jones, H. E.; Madden, T.; Gee, J. M.; Harper, M. E.; Barrow, D.; Wakeling, A. E.; Nicholson, R. I. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen resistant MCF-7 cells. Endocrinology 2003, 144, 1032-1044.
68. Normanno, N.; Di Maio, M.; De Maio, E.; De Luca, A.; de Matteis, A.; Giordano, A.; Perrone, F. NCI-Naple Breast Cancer Group. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr. Relat. Cancer 2005, 12, 721-747.
69. Shim, W. S.; Conaway, M.; Masamura, S.; Yue, W.; Wang, J. P.; Kmar, R.; Santen, R. J. Estradiol Hypersensitivity and MitogenActivated Protein Kinase Expression in Long-Term Estrogen Deprived Human Breast Cancer Cells in vivo. Endocrinology 2000, 141, 396-405.
70. Cho, H.; Ng, P. A.; Katzenellenbogen, B. S. Differential regulation of gene expression by estrogen in estrogen-growth independent and -dependent MCF-7 human breast cancer cell sublines. Mol. Endocrinol. 1991, 5, 1323-1330.
71. Wells, S. A.; Santen, R. J. Ablative procedure in patients with metastatic breast carcinoma. Cancer 1984, 53, 762-765.
72. Johnston, S. R. Enhancing the efficacy of hormonal agents with selected targeted agents. Clin. Breast Cancer 2009, 9, S28-S36.
73. Wang, C. X.; Koay, D. C.; Edwards, A.; Lu, Z.; Mor, G.; Ocal, I. T.; Digiovanna, M. P. In vitro and in vivo effects of combination of Trastuzumab (Herceptin) and Tamoxifen in breast cancer. Breast Cancer Res. Treat. 2005, 92, 251-263.
74. Kaufman, B.; Mackey, J. R.; Clemens, M. R.; Bapsy, P. P.; Vaid, A.; Wardley, A.; Tjulandin, S.; Jahn, M.; Lehle, M.; Feyereislova, A.; Révil, C.; Jones, A. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J. Clin. Oncol. 2009, 27, 5529-5537.
75. Johnston, S.; Pippen, J. Jr.; Pivot, X.; Lichinitser, M.; Sadeghi, S.; Dieras, V.; Gomez, H. L.; Romieu, G.; Manikhas, A.; Kennedy, M. J.; Press, M. F.; Maltzman, J.; Florance, A.; O'Rourke, L.; Oliva, C.; Stein, S.; Pegram, M. Lapatinib Combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 2009, 27, 5538-5546.
76. Martin, L. A.; Head, J. E.; Pancholi, S.; Salter, J.; Quinn, E.; Detre, S.; Kaye, S.; Howes, A.; Dowsett, M.; Johnston, S. R.The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo. Mol. Cancer Ther. 2007, 6, 2458-2467.
77. Li, T.; Christos, P. J.; Sparano, J. A.; Hershman, D. L.; Hoschander, S.; O'Brien, K.; Wright, J. J.; Vahdat, L. T. Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205. Ann. Oncol. 2009, 20, 642-647.
78. Baselga, J.; Semiglazov, V.; van Dam, P.; Manikhas, A.; Bellet, M.; Mayordomo, J.; Campone, M.; Kubista, E.; Greil, R.; Bianchi, G.; Steinseifer, J.; Molloy, B.; Tokaji, E.; Gardner, H.; Phillips, P.; Stumm, M.; Lane, H. A.; Dixon, J. M.; Jonat, W.; Rugo, H. S. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol. 2009, 27, 2630-2637.
79. Smollich, M.; Götte, M.; Fischgräbe, J.; Radke, I.; Kiesel, L.; Wülfing, P. Differential effects of aromatase inhibitors and anti-estrogens on estrogen receptor expression in breast cancer cells. Anticancer Res. 2009, 29, 2167-2171.
80. Spink, B. C.; Bennett, J. A.; Pentecost, B. T.; Lostritto, N.; Englert, N. A.; Benn, G. K.; Goodenough, A. K.; Turesky, R. J.; Spink, D. C. Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells. Toxicol. Appl. Pharmacol. 2009, 240, 355-366.
81. Barkhem, T.; Carlsson, B.; Nilsson, Y.; Enmark, E.; Gustafsson, J.; Nilsson, S. Differential response of estrogen receptor a and estrogen receptor b to partial estrogen agonists/antagonists. Mol. Pharmacol. 1998, 54, 105-112.
82. McInerney, E. M.; Katzenellenbogen, B. S. Different regions in activation function-1 of the human estrogen receptor required for antiestrogenand estradiol-dependent transcription activation. J. Biol. Chem. 1996, 271, 24172-24178.
83. Fawell, S. E.; White, R.; Hoare, S.; Sydenham, M.; Page, M.; Parker, M. G. Inhibition of estrogen receptor-DNA binding by the pure antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc. Natl. Acad. Sci. USA 1990, 87, 6883-6887.
84. Wijayaratne, A. L.; McDonnell, D. P. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J. Biol. Chem. 2001, 276, 35684-35692.
85. Cleator, S. J.; Ahamed, E.; Coombes, R. C.; Palmieri, C. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin. Breast Cancer 2009, 9, S6-S17.
86. Van der Auwera, I.; Elst, H. J.; Van Laere, S. J.; Maes, H.; Huget, P.; van Dam, P.; Van Marck, E. A.; Vermeulen, P. B.; Dirix, L. Y. The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br. J. Cancer 2009, 100(8), 1277-1286.
87. Morimoto, K.; Kim, S. J.; Tanei, T.; Shimazu, K.; Tanji, Y.; Taguchi, T.; Tamaki, Y.; Terada, N.; Noguchi, S. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci. 2009, 100(6), 1062-1068.
88. Simon, J. A.; Lange, C. A. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res. 2008, 647, 21-29.
89. Johnston, S. R. New strategies in estrogen receptor-positive breast cancer. Clin. Cancer Res. 2010, 16(7), 1979-1987.